Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Cystic Fibrosis

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jcf.2008.09.001PMID 18849202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Microbiology of Cystic Fibrosis

  2011cited by this paper
• ANNUAL REPORT ON STAPHYLOCOCCUS AUREUS BACTERAEMIA CASES IN DENMARK 2008 ( part I )

  2011cited by this paper
• Epidemiology of European Community-Associated Methicillin-Resistant Staphylococcus aureus Clonal Complex 80 Type IV Strains Isolated in Denmark from 1993 to 2004

  2007cited by this paper
• Maintenance Azithromycin Treatment in Pediatric Patients With Cystic Fibrosis: Long-Term Outcomes Related to Macrolide Resistance and Pulmonary Function

  2007cited by this paper
• Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomonas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr−/− Mice

  2007cited by this paper
• Macrolide-resistant Staphylococcus aureus colonization in cystic fibrosis patients: is there transmission to household contacts?

  2007cited by this paper
• Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial

  2006cited by this paper
• Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.

  2006influential reference
• Azithromycin Exhibits Bactericidal Effects on Pseudomonas aeruginosa through Interaction with the Outer Membrane

  2005cited by this paper
• Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

  2005cited by this paper
• Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.

  2005cited by this paper
• Epidemiology of Emerging Methicillin-Resistant Staphylococcus aureus (MRSA) in Denmark: a Nationwide Study in a Country with Low Prevalence of MRSA Infection

  2005influential reference
• Azithromycin Retards Pseudomonas aeruginosa Biofilm Formation

  2004cited by this paper
• Macrolide antibiotics for cystic fibrosis.

  2004cited by this paper
• Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.

  2003cited by this paper
• Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

  2003cited by this paper
• Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial

  2002cited by this paper
• Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects.

  2002cited by this paper
• Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.

  2002cited by this paper
• Azithromycin Inhibits Quorum Sensing in Pseudomonas aeruginosa

  2001cited by this paper
• Anti‐inflammatory effects of macrolides in lung disease *

  2001cited by this paper
• Anti-inflammatory activity of macrolide antibiotics.

  2000cited by this paper
• Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin.

  1998cited by this paper
• Long-term azithromycin may improve lung function in children with cystic fibrosis.

  1998cited by this paper
• Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin

  1996cited by this paper
• Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides.

  1995cited by this paper
• Diffuse panbronchiolitis and cystic fibrosis: East meets West.

  1994cited by this paper
• Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.

  1993cited by this paper
• Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis.

  1991cited by this paper
• ANTIBIOTIC TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTION IN CYSTIC FIBROSIS

  1982influential reference
• Staphylococcus aureus in cystic fibrosis: antibiotic sensitivity and phage types during the latest decade. Investigation of the occurrence of protein A and some other properties of recently isolated strains in relation to the occurrence of precipitating antibodies.

  1975cited by this paper

• Macrolide antibiotics (including azithromycin) for cystic fibrosis.

  2024cites this paper
• Macrolide resistance through uL4 and uL22 ribosomal mutations in Pseudomonas aeruginosa

  2024cites this paper
• Carriage and transmission of macrolide resistance genes in patients with chronic respiratory conditions and their close contacts.

  2022cites this paper
• The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease

  2021cites this paper
• Low‐dose and long‐term azithromycin significantly decreases Staphylococcus aureus in the microbiome of refractory CRS patients

  2020cites this paper
• Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells

  2019cites this paper
• [Azithromycine and chronic bronchial diseases: For which patients? For which benefits? With what modalities?]

  2019cites this paper
• Efficacy of Azithromycin in a Mouse Pneumonia Model against Hospital-Acquired Methicillin-Resistant Staphylococcus aureus

  2019cites this paper
• Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment‐Emergent Respiratory Pathogens

  2018cites this paper
• Life-long antimicrobial therapy: where is the evidence?

  2018cites this paper
• Azithromycin for treatment of bronchiolitis obliterans syndrome in adult lung transplant recipients

  2017cites this paper
• Long-term oral antibiotic treatment : why, what, when and to whom?

  2017cites this paper
• Recurrent Acute Rhinosinusitis Prevention by Azithromycin in Children with Nonallergic Rhinitis.

  2017cites this paper
• Bronchiectasis in Children: Current Concepts in Immunology and Microbiology

  2017cites this paper
• Macrolide maintenance treatment for bronchiectasis

  2017cites this paper
• Immunomodulatory effects of macrolide antibiotics – part 2: advantages and disadvantage of macrolide maintenance therapy

  2016cites this paper
• Question 5: What is the role of macrolide antibiotics as anti-inflammatory treatment in Cystic fibrosis?

  2016cites this paper
• Comparison of therapeutic effects of topical azithromycin solution and systemic doxycycline on posterior blepharitis.

  2016cites this paper
• [National consensus regarding azithromycin use in cystic fibrosis].

  2015cites this paper
• Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo

  2015cites this paper
• Single Center Experience of Five Diffuse Panbronchiolitis Patients Clinically Presenting as Severe Asthma

  2015cites this paper
• Characterization of Staphylococcus aureus Strains Isolated from Czech Cystic Fibrosis Patients: High Rate of Ribosomal Mutation Conferring Resistance to MLSB Antibiotics as a Result of Long-Term and Low-Dose Azithromycin Treatment

  2015cites this paper
• Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections

  2014cites this paper
• Measurement and Correlation of Solubility of Azithromycin Monohydrate in Five Pure Solvents

  2014cites this paper
• Comparative study different brands of azithromycin tablets

  2014cites this paper
• Antibiotic prophylaxis in primary immune deficiency disorders.

  2013cites this paper
• Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.

  2013cites this paper
• Macrolide therapy in cystic fibrosis: new developments in clinical use

  2013cites this paper
• IL-17A in Human Respiratory Diseases: Innate or Adaptive Immunity? Clinical Implications

  2013cites this paper
• Evolution and Impact of Bacterial Drug Resistance in the Context of Cystic Fibrosis Disease and Nosocomial Settings

  2013cites this paper
• Antimicrobial resistance mechanisms of Staphylococcus aureus

  2013cites this paper
• Low dose macrolide administration for long term is effective for otitis media with effusion in children.

  2013cites this paper
• A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF.

  2013cites this paper
• Drug induced complications; can we do more?

  2013cites this paper
• Macrolide antibiotics for cystic fibrosis.

  2012cites this paper
• Symposium Summaries

  2012cites this paper
• Antibiotic Prevention of Acute Exacerbations of COPD Richard

  2012cites this paper
• Azithromycin in cystic fibrosis : pharmacokinetic and therapeutic aspects of maintenance therapy

  2012cites this paper
• Antibiotic prevention of acute exacerbations of COPD.

  2012cites this paper
• Open‐label, follow‐on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa

  2012cites this paper
• Anti-inflammatory therapies in bronchiectasis

  2011cites this paper
• Characterization of macrolide resistance genes in Haemophilus influenzae isolated from children with cystic fibrosis.

  2011cites this paper
• Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases

  2011cites this paper
• Susceptibility of bacterial isolates from community‐acquired infections in sub‐Saharan Africa and Asia to macrolide antibiotics

  2011cites this paper
• [Usefulness of macrolides as anti-inflammatories in respiratory diseases].

  2010cites this paper
• Immunomodulatory Effects of Macrolide Antibiotics – Part 2: Advantages and Disadvantages of Long-Term, Low-Dose Macrolide Therapy

  2010cites this paper
• Macrolide and Clindamycin Resistance in Streptococcus milleri Group Isolates from the Airways of Cystic Fibrosis Patients

  2010cites this paper
• Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.

  2010cites this paper
• [Usefulness of macrolides as anti-inflammatories in respiratory diseases].

  2010cites this paper
• The role of azithromycin in patients with cystic fibrosis.

  2010cites this paper
• Update on antibiotics for infection control in cystic fibrosis

  2009cites this paper